Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Q3 FY25 Earnings Presentation
25 slides from Lumos Diagnostics's earnings presentation, May 6, 2025
Slide 1: Q3 FY25 Investor Briefing
For personal use only Lumos Diagnostics Holdings Limited Q3 FY25 Investor Briefing 6 May 2025 Financial information is shown in USD unless otherwise stated. www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of For personal use
Slide 3: Company Overview
For personal use only Company Overview
Slide 4: Who is Lumos and why do we exist?
Lumos develops, manufactures For personal use only Who is Lumos and distributes innovative and why diagnostic products do we exist? – delivering actionable information, in real time, at the point-of-care. Improve the practice of medicine. © Lumos Diagnostics , all rights reserved 4
Slide 5: Unique Value Creation
Unique Value Creation Solving Unmet Medical Needs For personal use only Developed and launched one of a kind proprietary point-of- care diagnostic product - FebriDx Transformational development agreements with the world’s leading global women’s health company – Hologic Currently developing women's h
Slide 6: Lumos Business Overview
Lumos Business Overview For personal use only Lumos offers end-to-end point of care (POC) diagnostic test PRODUCTS COMMERCIAL SERVICES development, from initial assay creation to high-volume manufacturing. We develop FebriDx & Women’s Development Contract and sell our own tests and also ViraDx Healt
Slide 7: Key Q3 FY25 Highlights
For personal use only Key Q3 FY25 Highlights
Slide 8: Key Highlights from Q3 FY25
Key Highlights from Q3 FY25 For personal use only Revenue of US$3.5 million for the quarter, up Product revenue was up 17% and Services Additional FebriDx® agreements completed in 21% compared to prior quarter (Q2 FY25 - revenue was up 22% on Q2 FY25. the U.S. 1) MedPro Associates and 2) U.S. US$2.9
Slide 9: Financials Summary
Financials Summary (Quarterly, US$ in thousands) Revenue ($’000) Revenue Mix Net Cash Generation ($’000)* For personal use only 100% $4,340 $3,117 $4,025 $3,421 $3,470 80% $2,012 $2,885 60% 40% 20% -$1,583 -$2,791 0% -$3,980 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3 FY25 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q3FY
Slide 10: Products Division
For personal use only Products Division
Slide 11: FebriDx Update
FebriDx® Update Distribution agreements For personal use only Two new distribution agreements signed in the US with: • MedPro Associates – across national hospital and primary care markets. • U.S. Defense Logistics Agency (DLA) awarded FebriDx a Distribution and Pricing Agreement (DAPA) which author
Slide 12: FebriDx Update cont'd
FebriDx® Update ...cont'd Medicare US payor coverage adoption • Effective from April 2025, FebriDx® has been added to the For personal use only Medicare Fee Schedule in four of the seven Medicare Administration Contractors (MACs) regions - Palmetto, Novitas, First Coast Service Options and Noridian
Slide 13: FebriDx CLIA Waiver Update
FebriDx® CLIA Waiver Update BARDA partnership agreement | October 2024 For personal use only To support CLIA waiver and pediatric studies: non-dilutive funding up to US$8.3m • US$3.0m to support CLIA waiver study • US$5.3m to support pediatric study (children under 12yrs old) • Payments based on ach
Slide 14: ViraDx
ViraDx Point-of-Care test for key respiratory infections ViraDx highly relevant POC test for post-pandemic environment For personal use only • SARS-CoV-2 pandemic increased consumer and healthcare point-of-care testing • ViraDx is a 3-in-1 test for COVID-19/Flu A/Flu B ViraDx market update • ViraDx
Slide 15: Lumos Future Products
Lumos Future Products Women’s Sexual Health - $10B For personal use only 1-2 DAYS Prevalence Clinical Need POC Diagnostic Opportunity Affects 30%-40% of women globally. Multiple infectious organisms. Rapid & accurate testing close to the >10M heath care visits annually in the Similar symptoms / hard
Slide 16: Women's Sexual Health – The Opportunity
Women’s Sexual Health – The Opportunity IN CLINIC TESTING EXTERNAL LAB TESTING For personal use only Physical Exam Microscopic Exam Pathogen Testing Pathogen Testing 1-5 DAYS Practice Current Majority of clinics do not have in Instead, clinics send out testing to Lumos Women’s Sexual Health POC test
Slide 17: Lumos Product Roadmap | Women's Sexual Health
Lumos Product Roadmap | Women’s Sexual Health CURRENT - DISTRIBUTION FUTURE - LUMOS POC PRODUCTS GYN CLINIConly Revenue & Market Learning Pathogen Detection | Visual & Reader Interpretation URGENT CARE For personal use & Lumos – As a Distributer Lumos Products – Visual Read Lumos Products on Lumos R
Slide 18: Commercial Services Division
For personal use only Commercial Services Division © Lumos Diagnostics . All rights reserved. 18
Slide 19: Commercial Services Overview
Commercial Services Overview For personal use only Lumos works directly with clients to develop and deliver custom built, commercially viable point-of-care (POC) test solutions that meet business and end user needs. Broad POC immunoassay development Deep POC market insight expertise over a range of
Slide 20: How we add value to partners
How we add value to partners We work with partners through the whole diagnostic test product development cycle, then provide support once their products are in market. For personal use only Customer launch and support Manufacture Clinical studies Verification and validation of requirements Conduct f
Slide 21: Hologic - Strategic Partnership
Hologic - Strategic Partnership Fetal Fibronectin (fFN)1 For personal use only • fFN is a biomarker indicating a heightened risk of pre-term delivery and is the largest segment of the pre-term birth diagnostic test kit market of US$420m p.a.2 • Two agreements signed in FY24 for the development of an
Slide 22: Hologic - fFN Product development overview and opportunity
Hologic - fFN Product development overview and opportunity For personal use only Current test: Next generation test Hologic – the opportunity ahead Rapid fFN TLiQ concept (mock-up) Verification Clinical and validation study Manufacturing Second test development and IP © Lumos Diagnostics . All right
Slide 23: Key Priorities
For personal use only Key Priorities © Lumos Diagnostics . All rights reserved. 23
Slide 24: Key Priorities
Key Priorities For personal use only Continue to monitor and Incorporate FDA feedback Progress to formal Continue to drive FebriDx Deliver on Hologic fFN implement strategies to from the FDA pre- product development on product awareness and development milestones - maintain and improve the submissio
Slide 25: For personal use only
For personal use only www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 25
Lumos Diagnostics Holdings — Q3 FY25 Earnings Presentation on 6ix